Private Capital Advisors Inc. Trims Stake in Thermo Fisher Scientific Inc. $TMO

Private Capital Advisors Inc. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the second quarter, Holdings Channel.com reports. The institutional investor owned 29,514 shares of the medical research company’s stock after selling 431 shares during the period. Thermo Fisher Scientific makes up approximately 1.5% of Private Capital Advisors Inc.’s portfolio, making the stock its 17th largest position. Private Capital Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $11,967,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in TMO. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. GAMMA Investing LLC lifted its stake in shares of Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after purchasing an additional 877 shares during the period. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Thermo Fisher Scientific by 1.8% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 38,154 shares of the medical research company’s stock worth $18,986,000 after purchasing an additional 691 shares during the period. Finally, XML Financial LLC lifted its stake in shares of Thermo Fisher Scientific by 11.1% during the 1st quarter. XML Financial LLC now owns 959 shares of the medical research company’s stock worth $477,000 after purchasing an additional 96 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.9%

Shares of NYSE TMO opened at $559.48 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a market cap of $211.27 billion, a P/E ratio of 32.36, a P/E/G ratio of 3.14 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a fifty day moving average price of $499.00 and a 200 day moving average price of $450.49.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company’s revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm earned $5.37 earnings per share. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on TMO shares. HSBC restated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a report on Thursday, July 24th. Robert W. Baird upped their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Finally, JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Fifteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $581.72.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.